Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed clear cell kidney cancer, meeting 1 of the following criteria:
• •* Measurable metastatic disease
• •* Locally unresectable disease
• •No history of known brain metastases that have not been adequately treated with radiotherapy and/or surgery
• •Must have received ≥ 1 prior systemic therapy for metastatic or unresectable renal cell carcinoma
• •PATIENT CHARACTERISTICS:
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• •Absolute neutrophil count \> 1,500/mm³
• •Platelet count \> 100,000/mm³
• •Hemoglobin \> 8 g/dL
• •Bilirubin \< 1.5 times upper limit of normal (ULN)
• •Serum glutamic oxaloacetic transaminase(SGOT) and Serum glutamic pyruvic transaminase(SGPT) \< 2.5 times ULN
• •Creatinine \< 1.5 times ULN
• •No New York Heat Association grade III-IV cardiac disease
• •No other malignancy within the past 5 years except basal cell skin cancer, cervical carcinoma in situ, or insignificant or inactive disease
• •No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)
• •No severe or uncontrolled medical disease
• •No gastrointestinal disease or impairment that would hinder the absorption of everolimus
• •No uncontrolled diabetes
• •No chronic renal disease
• •No active uncontrolled infection
• •No congestive heart failure
• •No myocardial infarction within the past 6 months
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •More than 2 weeks since prior major surgery
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin C)
• •More than 4 weeks since prior immunotherapy
• •More than 4 weeks since other prior investigational agents
• •No prior radiotherapy to \> 25% of bone marrow
• •No prior treatment with an mammalian target of rapamycin(mTOR) inhibitor
• •No concurrent therapeutic warfarin